Back to Journals » Drug Design, Development and Therapy » Volume 7

Long-acting preparations of exenatide

Authors Cai Y, Wei L, Ma L, Huang X, Tao A, Liu Z, Yuan W

Received 19 April 2013

Accepted for publication 5 June 2013

Published 5 September 2013 Volume 2013:7 Pages 963—970


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Yunpeng Cai,1,2,* Liangming Wei,3,* Liuqing Ma,2 Xiwen Huang,2 Anqi Tao,2 Zhenguo Liu,1 Weien Yuan1,2

1Department of Neurology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, 2School of Pharmacy, Shanghai JiaoTong University, 3Key Laboratory for Thin Film and Microfabrication Technology, Ministry of Education, Research Institute of Micro/Nanometer Science and Technology, Shanghai JiaoTong University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Abstract: Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by preparing sustained-release dosage forms, modifying its structure, gene therapies, and other means. This review summarizes recent advances in long-acting exenatide preparations.

Keywords: exendin-4, diabetes mellitus type 2, sustained release, long acting, extended release, microsphere

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.